Cited by 28Glioma Diagnosis and TreatmentPhotodynamic Therapy Research StudiesOptical Imaging and Spectroscopy Techniques

Double dose of 5-aminolevulinic acid and its effect on protoporphyrin IX accumulation in low-grade glioma

Open access
Suero Molina, Eric, Black, David, Kaneko, Sadahiro, Müther, Michael, Stummer, Walter·2022·Journal of Neurosurgery

Abstract

OBJECTIVE: Administration of 5-aminolevulinic acid (5-ALA) does not regularly elicit fluorescence in low-grade glioma (LGG) at currently established doses and timing of administration. One explanation may be differences in blood-brain barrier (BBB) integrity compared to high-grade glioma. The authors hypothesized that for a BBB semipermeable to 5-ALA there might be a relationship between plasma 5-ALA concentration and its movement into the brain. A higher dose would elicit more 5-ALA conversion into protoporphyrin IX (PPIX). The authors present a case series of patients harboring LGG who received higher doses of 5-ALA. METHODS: Patients undergoing surgery for indeterminate glioma later diagnosed as LGG were included in this study. 5-ALA was administered at a standard dose of 20 mg/kg body weight (bw) 4 hours prior to induction of anesthesia. A subgroup of patients received a higher dose of 40 mg/kg bw. Fluorescence was evaluated visually and PPIX concentration (cPPIX) was determined ex vivo by hyperspectral measurements in freshly extracted tissue. All adverse events were recorded. RESULTS: A total of 23 patients harboring diffuse low-grade astrocytomas (n = 19) and oligodendrogliomas (n = 4) were analyzed. Thirteen patients received 20 mg/kg bw, and 10 patients received 40 mg/kg bw of 5-ALA. In the 20 mg/kg group, 30.8% (4 of 13) of tumors harbored areas of visible fluorescence, compared to 60% of cases (n = 6 of 10) with 40 mg/kg bw. The threshold to visibility was 1 μg/ml in both groups. Measured over all biopsies, the mean cPPIX was significantly higher in the double-dose group (1.8 vs 0.45 μg/ml; p < 0.001). In non-visibly fluorescent tissue the mean cPPIX was 0.146 μg/ml in the 20 mg/kg and 0.347 μg/ml in the 40 mg/kg group, indicating an increase of 138% (p < 0.001). CONCLUSIONS: These observations demonstrate different regions with different levels of PPIX accumulation in LGG. With higher 5-ALA doses cPPIX increases, leading to more regions surpassing the visibility threshold of 1 μg/ml. These observations can be explained by the fact that the BBB in LGG is semipermeable to 5-ALA. Higher 5-ALA doses result in more PPIX conversion, an observation with implications for future dosing in LGG.

Integrity signals

Registry

Crossref · 10.3171/2021.12.jns211724

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Doubling the dose of ALA to 40 mg/kg or delaying the examination time to 7 and 8 h after ALA administration increases PpIX fluorescence in low-grade gliomas.

    “There are studies showing that either doubling the dose of ALA to 40 mg/kg [55] or delaying the examination time to 7 and 8 h after ALA administration [53] increases the PpIX fluorescence in low-grade gliomas.”
  • Doubling the dose of ALA from 20 to 40 mg/kg significantly increases tumor PpIX fluorescence and doubles the rate of tumor detection in low-grade glioma patients.

    “This notion is supported by the finding that doubling the dose of ALA from 20 to 40 mg/kg not only significantly increases tumor PpIX fluorescence but also doubles the rate of tumor detection in low-grade glioma patients [55].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Suero Molina, E., Black, D., Kaneko, S., Müther, M., & Stummer, W.
Affiliations
  • Department of Neurosurgery, University Hospital of Münster;
  • Carl Zeiss (Germany) (DE)
  • Hokkaido University (JP)
  • University Hospital Münster (DE)
Venue
Journal of Neurosurgery
Published
2022-10-01
Volume
137
Issue
4
Pages
943-952
ISSN
  • 0022-3085 (ISSN-L)
  • 1933-0693
OpenAlex
W4214569527
Cited by
28
References
6
Citations by year
2026: 5 · 2025: 3 · 2024: 13 · 2023: 5 · 2022: 2
FWCI
3.57
Type
journal article
Language
en
Open access
Locations
  • Journal of neurosurgery (publishedVersion)
  • PubMed (publishedVersion)
Funders
Carl Zeiss Meditec AG
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Optical Imaging and Spectroscopy Techniques
Keywords
5-aminolevulinic acid, low-grade glioma, protoporphyrin IX, fluorescence-guided surgery, blood-brain barrier permeability, diffuse astrocytoma, oligodendroglioma, tumor fluorescence, hyperspectral imaging, glioma grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review